Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Completed · Phase 2
Conditions studied: Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
In brief
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic therapy. Patients received an oral once-daily total dose of 300 mg derazantinib capsules.
Key facts
- Study ID
- NCT03230318
- Run by
- Basilea Pharmaceutica
- People needed
- 148
- Starts
- 2017-09-28
- Expected to finish
- 2022-10-25
- Last updated by the study team
- 2023-12-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Phoenix, Arizona, United States
- Mayo Clinic — Jacksonville, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers — New York, New York, United States
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
- The University of Texas Southwestern Medical Center — Dallas, Texas, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- University of Washington Medical Center — Seattle, Washington, United States
- Hôpital Erasme — Brussels, Belgium
- Cliniques Universitaires Saint-Luc — Brussels, Belgium
- Antwerp University Hospital — Edegem, Belgium
- Tom Baker Cancer Centre — Calgary, Alberta, Canada
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- CHU Grenoble Alpes — La Tronche, France
- Gustave Roussy — Villejuif, France
- Universitätsklinikum Frankfurt — Frankfurt am Main, Germany
- Universitätsklinikum Hamburg-Eppendorf (UKE) — Hamburg, Germany
- Medizinische Hochschule Hannover (MHH) — Hanover, Germany
- Universitätsklinikum des Saarlandes — Homburg, Germany
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz — Mainz, Germany
- St. James's Hospital — Dublin, Ireland
- Sant'Orsola-Malpighi Hospital, University of Bologna — Bologna, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.